<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cyproheptadine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cyproheptadine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cyproheptadine: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9311" href="/d/html/9311.html" rel="external">see "Cyproheptadine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12349" href="/d/html/12349.html" rel="external">see "Cyproheptadine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1057570"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihistamine</span></li></ul></div>
<div class="block dop drugH1Div" id="F155731"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c11414eb-e4a9-4f52-b5ec-67ffd22dabf5">Allergic conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic conditions (nonacute):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed or BSA-directed dosing: Children ≥2 years and Adolescents: Oral: 0.25 mg/kg/day or 8 mg/m<sup>2</sup>/day in 2 to 3 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">2 to 6 years: Oral: 2 mg every 8 to 12 hours; maximum daily dose: 12 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">7 to 14 years: Oral: 4 mg every 8 to 12 hours; maximum daily dose: 16 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">≥15 years: Initial: Oral: 4 mg every 8 hours; titrate to effect; usual range: 12 to 16 mg/day although some patients may require up to 32 mg; maximum daily dose: 0.5 mg/kg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe0f5f5f-0320-4623-b810-c594fc16e6ca">Appetite stimulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Appetite stimulation: </b>Limited data available; dosing regimens variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30825493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30825493'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing: Children ≥2 years and Adolescents: Oral: 0.25 mg/kg/day divided twice daily; age-dependent maximum daily dose: ≤6 years: 12 mg/<b>day</b>; 7 to 14 years: 16 mg/<b>day</b>; ≥15 years: 32 mg/<b>day</b>. Dosing based on an open-label trial of 66 pediatric cancer patients (median age: 11.7 years; range: 3 to 19 years) which reported 76% response rate (either weight gained or stabilized); mean weight gain: 2.6 kg (range: −0.1 to 10 kg); in a subset analysis, patients &gt;9 years showed a greater response than younger patients as did patients with hematologic malignancies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18989154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18989154'])">Ref</a></span>). In malnourished patients (n=77, ages 2 to 5 years), use was associated with significantly higher BMI compared to controls after 8 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26019782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26019782'])">Ref</a></span>). In patients with multifactorial feeding problems (eg, cleft palate, neurodevelopmental disorders), cyproheptadine improved mealtime and feeding behaviors as well as weight for age z-scores (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24941960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24941960'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing: Children ≥5 years and Adolescents: Oral: Initial: 2 mg every 6 hours (4 times daily) for 1 week; if tolerated, increase dose to 4 mg every 6 to 8 hours; one trial did not titrate dosing and started with target maintenance dose (4 mg three times daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22544046','lexi-content-ref-15211696','lexi-content-ref-16015665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22544046','lexi-content-ref-15211696','lexi-content-ref-16015665'])">Ref</a></span>). Dosing based on a short-term (12-week) double-blind, placebo-controlled trial (n=8 treatment group) and a long-term (1-year) open-label trial (n=12) in patients with cystic fibrosis (CF); results showed significant increases in weight gain (3.4 kg vs 1.1 kg in placebo); long-term results showed a generally sustained effect (eg, no further weight loss or some additional weight gain) over study duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15211696','lexi-content-ref-16015665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15211696','lexi-content-ref-16015665'])">Ref</a></span>). A placebo-controlled trial including 25 patients with CF (age ≥5 years) utilized a 12 mg/day dose (4 mg 3 times daily); after 12 weeks of therapy, use was associated with significant increase in weight compared to placebo (1.61 kg vs 0.67 kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22544046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22544046'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7fc4235-c695-4f6f-8b85-6a2ed65e8502">Cyclic vomiting syndrome, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, prophylaxis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Prophylaxis is recommended for patients experiencing frequent symptoms (eg, monthly) or severe symptoms (eg, requiring hospitalization, lasting &gt;2 days, resulting in significant school/work absences). Cyproheptadine is a first-line choice for prophylaxis in children &lt;5 years of age; however, it is less commonly used for older children and adolescents due to adverse effects (eg, appetite stimulation, weight gain); other drugs are more likely to be effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24898244','lexi-content-ref-30076469','lexi-content-ref-18728540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24898244','lexi-content-ref-30076469','lexi-content-ref-18728540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Oral: 0.25 to 0.5 mg/kg/day in 1 to 3 divided doses; maximum daily dose: 12 mg/<b>day</b>. <b>Note:</b> Lower starting doses followed by titration have also been reported; some experts have used a once-daily dose at bedtime to prevent daytime sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9374568','lexi-content-ref-28719594','lexi-content-ref-30076469','lexi-content-ref-18728540','lexi-content-ref-33224097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9374568','lexi-content-ref-28719594','lexi-content-ref-30076469','lexi-content-ref-18728540','lexi-content-ref-33224097'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="859a523a-3fe2-4f90-85f2-f909ce807dbd">Functional abdominal pain; refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Functional abdominal pain (dyspeptic syndrome); refractory:</b> Limited data available: Infants ≥9 months, Children, and Adolescents ≤14 years: Oral: Reported range: 0.04 to 0.6 mg/kg/day in divided doses 2 to 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26308312','lexi-content-ref-23419589','lexi-content-ref-18971897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26308312','lexi-content-ref-23419589','lexi-content-ref-18971897'])">Ref</a></span>); age-dependent maximum daily doses: Infants and Children 2 to 6 years: 12 mg/day; Children and Adolescents 7 to 14 years: 16 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26308312','lexi-content-ref-18971897','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26308312','lexi-content-ref-18971897','lexi-content-ref-Manu.1'])">Ref</a></span>). Dosing based on prospective and retrospective trials. In a prospective, double-blind, placebo-controlled trial including 29 patients with functional abdominal pain (age range: 2 to 14 years; n= 15 treatment group), results showed significant improvement in pain frequency and intensity with 2 weeks of cyproheptadine (0.25 to 0.5 mg/kg/day divided twice daily) compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18971897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18971897'])">Ref</a></span>). A retrospective, open-label trial of 80 pediatric patients (median age: 9.8 years; range: 9 months to 20 years) with dyspeptic symptoms (eg, nausea, early satiety, abdominal pain, retching after fundoplication and vomiting) which failed to respond to conventional therapy received 0.04 to 0.6 mg/kg/day of cyproheptadine (median effective dose: 0.22 mg/kg/day); the observed response rate was 55%; a higher response rate (86%) was seen with patients who experienced retching post-Nissen fundoplication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419589']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419589'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention:</b> Limited data available: Children ≥3 years and Adolescents: Oral: Usual range: 0.2 to 0.4 mg/kg/day divided twice daily; doses up to 1.5 mg/kg/day in divided doses 2 to 3 times daily have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23055860','lexi-content-ref-26788131','lexi-content-ref-Kliegman.1','lexi-content-ref-16554256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23055860','lexi-content-ref-26788131','lexi-content-ref-Kliegman.1','lexi-content-ref-16554256'])">Ref</a></span>); age-dependent maximum daily doses: Children 3 to 6 years: 12 mg/day; Children ≥7 years and Adolescents: 16 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16554256','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16554256','lexi-content-ref-Manu.1'])">Ref</a></span>); experience suggests younger patients more tolerant of common cyproheptadine side effects (ie, sedation, increased appetite) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15623677','lexi-content-ref-15012660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15623677','lexi-content-ref-15012660'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf69eee4-1d62-4585-adb2-3d133f4b00f9">Spasticity associated with spinal cord damage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spasticity associated with spinal cord damage:</b> Limited data available; efficacy results variable: Oral: Children ≥12 years and Adolescents: 4 mg at bedtime; increase by a 4 mg dose every 3 to 4 days; mean daily dose: 16 mg/day in divided doses; maximum daily dose: 36 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9826984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9826984'])">Ref</a></span>). In the most rigorous evaluation, a double-blind, placebo-controlled, crossover trial of 16 hemiplegic pediatric patients (age range: 4 to 18 years), cyproheptadine (relatively low dose: 1 to 2 mg/day) had no statistical evidence of an effect on gait nor improvement in spasticity parameters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10200409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10200409'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090487"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, elimination is diminished in renal insufficiency.</p></div>
<div class="block dohp drugH1Div" id="F51090488"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling</p></div>
<div class="block doa drugH1Div" id="F155712"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9311" href="/d/html/9311.html" rel="external">see "Cyproheptadine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="84672951-7bfd-491d-afb6-a920dd60ca13">Appetite, decreased secondary to chronic disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Appetite, decreased secondary to chronic disease (off-label use):</b>
<b>Oral:</b> Initial: 2 mg 4 times per day for 1 week, then 4 mg 4 times per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15211696','lexi-content-ref-16015665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15211696','lexi-content-ref-16015665'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32d65441-412d-4c68-8219-74eea0583f09">Serotonin syndrome, moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome (serotonin toxicity), moderate (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients with agitation despite discontinuation of serotonergic agent(s), adequate sedation (eg, with a benzodiazepine), and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 12 mg once followed by 2 mg every 2 hours until clinical response. Maintenance: 4 to 8 mg every 6 hours as needed. Maximum dose: 32 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991193"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, elimination is diminished in renal insufficiency.</p></div>
<div class="block doha drugH1Div" id="F50988309"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F6792013"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class (antihistamines) and may not be specifically reported for cyproheptadine.</p>
<p style="text-indent:0em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Extrasystoles, hypotension, palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, cholestasis (Larrey 1987), constipation, diarrhea, epigastric pain, increased appetite, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Difficulty in micturition, early menses, urinary frequency, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Chertoff 2014), hepatic impairment, hepatitis (Larrey 1987), jaundice (Henry 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, chills, confusion, dizziness, drowsiness, euphoria, excitement, fatigue, hallucination, headache, hysteria, insomnia, irritability, nervousness, neuritis, paresthesia, restlessness, sedated state, seizure, tightness in chest or throat, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Labyrinthitis (acute), tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry nose, dry throat, nasal congestion, thickening of bronchial secretions, wheezing</p></div>
<div class="block coi drugH1Div" id="F155697"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Use in newborn or premature infants or breastfeeding mothers; hypersensitivity to cyproheptadine or any component of the formulation; monoamine oxidase inhibitor therapy; angle-closure glaucoma; stenosing peptic ulcer; symptomatic prostatic hypertrophy; bladder neck obstruction; pyloroduodenal obstruction; elderly, debilitated patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F155682"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Antihistamines are more likely to cause dizziness, sedation, and hypotension and other anticholinergic effects in older adults; avoid use (Beers Criteria [AGS 2019]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Antihistamines may cause excitation in young children.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878405"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Excessive dosages of antihistamine in infants and young children may cause hallucinations, CNS depression, seizures, and death. Use with caution and use the lowest effective dose in children ≥2 years of age and avoid concomitant use with other medications having respiratory depressant effects.  </p></div>
<div class="block foc drugH1Div" id="F155692"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/5 mL (473 mL, 946 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg</p></div>
<div class="block geq drugH1Div" id="F155678"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323084"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (Cyproheptadine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/5 mL (per mL): $0.14 - $0.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cyproheptadine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $0.15 - $1.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612469"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer liquid preparations with an accurate measuring device.</p></div>
<div class="block sts drugH1Div" id="F25188839"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oral syrup: Store at 20°C to 25°C (68°F to 77°F); protect from light. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oral tablets: Store at 20°C to 25°C (68°F to 77°F). </p></div>
<div class="block usep drugH1Div" id="F53566293"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Perennial and seasonal allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis caused by inhalant allergens and foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; cold urticaria; dermatographism; adjunctive anaphylactic therapy (FDA approved in ages ≥2 years and adults); has also been used to promote weight gain by appetite stimulation in various disease states (eg, cystic fibrosis, cancer-related cachexia), migraine prophylaxis, prevention of episodes of cyclic vomiting, management of refractory dyspeptic symptoms, and treatment of spasticity associated with spinal cord damage.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Although FDA approved as adjunctive therapy for anaphylaxis, H<sub>1</sub> and H<sub>2</sub> antihistamine agents are generally considered second or third line (not for initial or sole treatment of anaphylaxis); preferred H<sub>1</sub> antihistamine agents include diphenhydramine or nonsedating cetirizine; cyproheptadine is not considered a therapeutic option (AAAAI/ACAAI/JCAAI [Lieberman 2015]; WAO [Simons 2015]).</p></div>
<div class="block mst drugH1Div" id="F155758"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cyproheptadine may be confused with cyclobenzaprine</p>
<p style="text-indent:-2em;margin-left:4em;">Periactin may be confused with Percodan, Persantine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Cyproheptadine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic. Exposure to concurrent anticholinergic drugs also increases risk of falls, delirium, and dementia; consider total anticholinergic burden when conducting medication reviews (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Periactin brand name for cyproheptadine [US, multiple international markets] may be confused with Perative brand name for an enteral nutrition preparation [multiple international markets] and brand name for ketoconazole [Argentina]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299111"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F155687"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the CNS depressant effect of Cyproheptadine. Cyproheptadine may diminish the therapeutic effect of Fenfluramine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Cyproheptadine may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking cyproheptadine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: Cyproheptadine may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F14389393"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Outcome data following maternal use of cyproheptadine during pregnancy are limited (Heinonen 1977; Kasperlik-Załuska 1980; Khir 1982; Sadovsky 1972). Per the product labeling, based on two studies, an increased risk of congenital abnormalities was not observed following maternal use of cyproheptadine during the first, second, or third trimesters in two studies of pregnant patients; however, the possibility of harm cannot be ruled out.</p></div>
<div class="block pha drugH1Div" id="F155681"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A potent antihistamine and serotonin antagonist with anticholinergic effects; competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract (Paton 1985).</p></div>
<div class="block phk drugH1Div" id="F155696"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed (Graudins 1998)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily by hepatic glucuronidation to metabolites (Hintze 1975)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Metabolites: ~16 hours (Paton 1985)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Metabolites: 6 to 9 hours (Paton 1985)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~40% primarily as metabolites); feces (2% to 20%, &lt;6% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51220869"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination is diminished in renal insufficiency.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F155701"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Azulina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arictin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Nurabol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cyprotol | Peritol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Periatin | Preptin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Nurabol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ciproactin | Viternum</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cyproheptadine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ciproheptadina | Periactin | Viternum</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Peritol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Peritol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Prolyn</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Periactin | Peritol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cyptadine | Triactin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Anarexol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Periactine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adekin | Periactin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Appetin | C.h. | Ciprodin | Cyprodin | Cyprogin | Cyproheptadine | Periact | Periactin | Qualiactin | U eatin | Uni-Heptadine | Uni-heptadine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Peritol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alphahist | Apeton | Arsigran | Cylat | Ennamax | Erphacyp | Esprocy | Glocyp | Graperide | Heptasan | Kensip | Lexahist | Nebor | New cypromin | Omesip | Poncohist | Procydin | Profut | Prohessen | Pronam | Pronicy | Pronimax</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Abitol | Add app | Afdigrow | Anabol | Anorexin | Apeat | Apectin | Apenorm | Apetamin | Apetone | Apetox | Apitol | App Up | Appetin pl | Appodin g | Appri | Aptivin | Bal Riactin | Cadictin | Cadlactin | Ciplactin | Cipron | Cym | Cyphoden | Cyprollion | Cyprotol | Cyptan | Cyptol | Eptocol | Hepdine | Heptadine | Heptidin | Hungree | Ibiapt | Ioplex | Lupactin | Lycip | Normatone | Osactin | Pepon | Peritol | Practin | Rarritol | Sp lysin | Toractin</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Afractin | Cibtaden | Citadine | Cyproctin | Cyprodad | Cyprodine | Cyprosaf | Periahist</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cyproatin | Cyproatin taiyo | Cyproatin towa | Cypromin | Cyptazin | Ifrasarl | Ifrasarl showa | Periactin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ciplactin | Plactinic | Uniactin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cyprodin | Periactin | Pratin | Prohethin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Periactin | Triactin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ciplactin | Peritol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ciplactin | Peritol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Antinorex | Apetine | Aractine | Nurabol | Periactine | Pernabol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Viternum</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cyproheptadine | Cyproheptadine HCL</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Curegold | Cyprigold | Cyproheptadine | Cypropek | Garylong | Rich apetie syrup | Vema tone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cyproheptadine HCL | Peritol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cyprodin | Periactin | Stanzar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Peritol | Protadina</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cyproheptadine HCL | Periactin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ciproral | Periactin | Supersan | Viternum</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Periactin | Triactin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Biohept | Ciproheptadina arena</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Peritol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Periactin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cyproheptadine | Cyprotin | Periactin | Pilian</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Peritol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anpro | Appedine | Baby | Bozo | Cycodine | Cyheptine | Cypro | Cyprodine | Cyprogin | Cyproheptadin | Cyproheptadine | Cypromed p | Cypromide | Cyprono | Cypropicco | Cyprosian | Cyprotec | Cyprotin | Kentidine | Mano | Periactin | Perry | Polytab | Pondnaheptin | Proretin | Star</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cipractine | Ciptadine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Prakten | Sipraktin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Antimin | Antisemin | Appitamine | Ceriatin | Chilieanzin | Cyhepdin | Cyllermin | Cypro | Cyprodin | Cyprodine | Cyproh | Cyprohepatadine | Cyproheptadine | Cyproheptadine HCL | Cypromin | Cypromine | Cytadine | Dariactin | Dechimin | Earmin | Feri | Fulimin | Huavine | Komian | Nekmin | Outallergin | Pelion | Periactin | Perian | Pilian | Piminton | Prozine | Serodine | Showmin | Synmin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Peritol | Peritonil</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Cypolive | Procip | Toractin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ciprogal</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cyprodin | Periactin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cipla-actin | Periactin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Apectine | Ciplactin | Cyproheptadine | Power apetite | Prodin | Super apeti</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9374568">
<a name="9374568"></a>Andersen JM, Sugerman KS, Lockhart JR, et al, "Effective Prophylactic Therapy for Cyclic Vomiting Syndrome in Children Using Amitriptyline or Cyproheptadine," <i>Pediatrics</i>, 1997, 100(6):977-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/9374568/pubmed" id="9374568" target="_blank">9374568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28719594">
<a name="28719594"></a>Badihian N, Saneian H, Badihian S, Yaghini O. Prophylactic therapy of cyclic vomiting syndrome in children: comparison of amitriptyline and cyproheptadine: a randomized clinical trial. <i>Am J Gastroenterol</i>. 2018;113(1):135-140. doi:10.1038/ajg.2017.194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/28719594/pubmed" id="28719594" target="_blank">28719594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23055860">
<a name="23055860"></a>Brenner M, Lewis D. The treatment of migraine headaches in children and adolescents. <i>J Pediatr Pharmacol Ther</i>. 2008;13(1):17-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/23055860/pubmed" id="23055860" target="_blank">23055860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25580444">
<a name="25580444"></a>Chertoff J, Alam S, Clark V. Cyproheptadine-induced acute liver failure. <i>ACG Case Rep J</i>. 2014;1(4):212-213. doi:10.14309/crj.2014.56<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/25580444/pubmed" id="25580444" target="_blank">25580444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18989154">
<a name="18989154"></a>Couluris M, Mayer JL, Freyer DR, Sandler E, Xu P, Krischer JP. The effect of cyproheptadine hydrochloride (Periactin) and megestrol acetate (Megace) on weight in children with cancer/treatment-related cachexia. <i>J Pediatr Hematol Oncol.</i> 2008;30(11):791-797.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/18989154/pubmed" id="18989154" target="_blank">18989154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24898244">
<a name="24898244"></a>Cristofori F, Thapar N, Saliakellis E, et al. Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome. <i>Aliment Pharmacol Ther</i>. 2014;40(3):309-317. doi:10.1111/apt.12822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/24898244/pubmed" id="24898244" target="_blank">24898244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chartwell.1">
<a name="Chartwell.1"></a>Cyproheptadine hydrochloride oral solution syrup [prescribing information]. Congers, NY: Chartwell Rx LLC; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Westminster.1">
<a name="Westminster.1"></a>Cyproheptadine hydrochloride tablets, USP [prescribing information]. Congers, NY: Chartwell Rx LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol.</i> 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22544046">
<a name="22544046"></a>Epifanio M, Marostica PC, Mattiello R, et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. <i>J Pediatr (Rio J)</i>. 2012;88(2):155-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/22544046/pubmed" id="22544046" target="_blank">22544046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9826984">
<a name="9826984"></a>Gracies JM, Nance P, Elovic E, et al, “Traditional Pharmacological Treatments for Spasticity. Part II: General and Regional Treatments,” <i>Muscle Nerve Suppl</i>, 1997, 6:S92-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/9826984/pubmed" id="9826984" target="_blank">9826984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9696181">
<a name="9696181"></a>Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. <i>J Emerg Med</i>. 1998;16(4):615-619. doi:10.1016/s0736-4679(98)00057-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/9696181/pubmed" id="9696181" target="_blank">9696181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30825493">
<a name="30825493"></a>Harrison ME, Norris ML, Robinson A, Spettigue W, Morrissey M, Isserlin L. Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review. <i>Appetite</i>. 2019;137:62-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/30825493/pubmed" id="30825493" target="_blank">30825493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heinonen.1">
<a name="Heinonen.1"></a>Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Publishing Sciences Group Inc. 1977.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-630329">
<a name="630329"></a>Henry DA, Lowe JM, Donnelly T. Jaundice during cyproheptadine treatment. <i>Br Med J</i>. 1978;1(6115):753. doi:10.1136/bmj.1.6115.753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/630329/pubmed" id="630329" target="_blank">630329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-234828">
<a name="234828"></a>Hintze KL, Wold JS, Fischer LJ. Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite. <i>Drug Metab Dispos</i>. 1975;3(1):1-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/234828/pubmed" id="234828" target="_blank">234828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15211696">
<a name="15211696"></a>Homnick DN, Homnick BD, Reeves AJ, Marks JH, Pimentel RS, Bonnema SK. Cyproheptadine is an effective appetite stimulant in cystic fibrosis. <i>Pediatr Pulmonol</i>. 2004;38(2):129-134. doi:10.1002/ppul.20043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/15211696 /pubmed" id="15211696 " target="_blank">15211696 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16015665">
<a name="16015665"></a>Homnick DN, Marks JH, Hare KL, Bonnema SK. Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. <i>Pediatr Pulmonol</i>. 2005;40(3):251-256. doi:10.1002/ppul.20265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/16015665 /pubmed" id="16015665 " target="_blank">16015665 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399. doi:10.1016/s0002-9378(11)90771-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26788131">
<a name="26788131"></a>Kacperski J, Kabbouche MA, O'Brien HL, Weberding JL. The optimal management of headaches in children and adolescents. <i>Ther Adv Neurol Disord</i>. 2016;9(1):53-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/26788131/pubmed" id="26788131" target="_blank">26788131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2187585">
<a name="2187585"></a>Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. <i>Cancer</i>. 1990;65(12):2657-2662. doi:10.1002/1097-0142(19900615)65:12&lt;2657::aid-cncr2820651210&gt;3.0.co;2-s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/2187585/pubmed" id="2187585" target="_blank">2187585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7437385">
<a name="7437385"></a>Kasperlik-Załuska A, Migdalska B, Hartwig W, et al. Two pregnancies in a woman with Cushing's syndrome treated with cyproheptadine. Case report. <i>Br J Obstet Gynaecol</i>. 1980;87(12):1171-1173. doi:10.1111/j.1471-0528.1980.tb04494.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/7437385/pubmed" id="7437385" target="_blank">7437385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7128894">
<a name="7128894"></a>Khir AS, How J, Bewsher PD. Successful pregnancy after cyproheptadine treatment for Cushing's disease. <i>Eur J Obstet Gynecol Reprod Biol</i>. 1982;13(6):343-347. doi:10.1016/0028-2243(82)90069-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/7128894/pubmed" id="7128894" target="_blank">7128894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10200409">
<a name="10200409"></a>Khodadadeh S, Holstein H, Purushothaman S, et al, "A Study of the Effect of Cyproheptadine on Gait in Hemiplegic Children," <i>Gait Posture</i>, 1998, 8(3):205-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/10200409/pubmed" id="10200409" target="_blank">10200409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3559100">
<a name="3559100"></a>Larrey D, Geneve J, Pessayre D, Machayekhi JP, Degott C, Benhamou JP. Prolonged cholestasis after cyproheptadine-induced acute hepatitis. <i>J Clin Gastroenterol</i>. 1987;9(1):102-104. doi:10.1097/00004836-198702000-00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/3559100/pubmed" id="3559100" target="_blank">3559100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15623677">
<a name="15623677"></a>Lewis D, Ashwal S, Hershey A, et al, "Practice Parameter: Pharmacological Treatment of Migraine Headache in Children and Adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society," <i>Neurology</i>, 2004, 63(12):2215-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/15623677/pubmed" id="15623677" target="_blank">15623677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15012660">
<a name="15012660"></a>Lewis DW, Diamond S, Scott D, et al, "Prophylactic Treatment of Pediatric Migraine," <i>Headache</i>, 2004a, 44(3):230-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/15012660/pubmed" id="15012660" target="_blank">15012660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16554256">
<a name="16554256"></a>Lewis DW, Winner P. The pharmacological treatment options for pediatric migraine: an evidence-based appraisal. <i>NeuroRx</i>. 2006;3(2):181-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/16554256/pubmed" id="16554256" target="_blank">16554256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728540">
<a name="18728540"></a>Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. <i>J Pediatr Gastroenterol Nutr</i>. 2008;47(3):379-393. doi:10.1097/MPG.0b013e318173ed39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/18728540/pubmed" id="18728540" target="_blank">18728540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018;177(10):1435-1442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015;115(5):341-384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26308312">
<a name="26308312"></a>Madani S, Cortes O, Thomas R. Cyproheptadine use in children with functional gastrointestinal disorders. <i>J Pediatr Gastroenterol Nutr</i>. 2016;62(3):409-413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/26308312/pubmed" id="26308312" target="_blank">26308312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928731">
<a name="3928731"></a>Messinis IE, Souvatzoglou A, Fais N, et al, "Histamine H1 Receptor Participation in the Control of Prolactin Secretion in Postpartum," <i>J Endocrinol Invest</i>, 1985, 8(2):143-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/3928731/pubmed" id="3928731" target="_blank">3928731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26019782">
<a name="26019782"></a>Najib K, Moghtaderi M, Karamizadeh Z, Fallahzadeh E. Beneficial effect of cyproheptadine on body mass index in undernourished children: a randomized controlled trial. <i>Iran J Pediatr</i>. 2014;24(6):753-758.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/26019782/pubmed" id="26019782" target="_blank">26019782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2866055">
<a name="2866055"></a>Paton DM and Webster DR. Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines). <i>Clin Pharmacokinet</i>. 1985;10(6):477-497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/2866055/pubmed" id="2866055" target="_blank">2866055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33224097">
<a name="33224097"></a>Raucci U, Borrelli O, Di Nardo G, et al. Cyclic vomiting syndrome in children. <i>Front Neurol</i>. 2020;11:583425. doi:10.3389/fneur.2020.583425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/33224097/pubmed" id="33224097" target="_blank">33224097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23419589">
<a name="23419589"></a>Rodriguez L, Diaz J, and Nurko S, "Safety and Efficacy of Cyproheptadine for Treating Dyspeptic Symptoms in Children," <i>J Pediatr</i>, 2013, Feb 16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/23419589/pubmed" id="23419589" target="_blank">23419589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18971897">
<a name="18971897"></a>Sadeghian M, Farahmand F, Fallahi GH, Abbasi A. Cyproheptadine for the treatment of functional abdominal pain in childhood: a double-blinded randomized placebo-controlled trial. <i>Minerva Pediatr</i>. 2008;60(6):1367-1374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/18971897/pubmed" id="18971897" target="_blank">18971897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4680134">
<a name="4680134"></a>Sadovsky E, Pfeifer Y, Polishuk WA, Sulman FG. The use of antiserotonin-cyproheptadine HCL in pregnancy: an experimental and clinical study. <i>Adv Exp Med Biol</i>. 1972;27:399-405. doi:10.1007/978-1-4684-3219-0_33<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/4680134/pubmed" id="4680134" target="_blank">4680134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24941960">
<a name="24941960"></a>Sant'Anna AM, Hammes PS, Porporino M, Martel C, Zygmuntowicz C, Ramsay M. Use of cyproheptadine in young children with feeding difficulties and poor growth in a pediatric feeding program. <i>J Pediatr Gastroenterol Nutr</i>. 2014;59(5):674-678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/24941960/pubmed" id="24941960" target="_blank">24941960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32001253">
<a name="32001253"></a>Shaker MS, Wallace DV, Golden DBK, et al; Joint Task Force on Practice Parameters Reviewers. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. <i>J Allergy Clin Immunol</i>. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/32001253/pubmed" id="32001253" target="_blank">32001253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525001">
<a name="26525001"></a>Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. <i>World Allergy Organ J</i>. 2015;8(1):32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/26525001/pubmed" id="26525001" target="_blank">26525001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8504557">
<a name="8504557"></a>Wians FH, Norton JT, and Wirebaugh, “False-Positive Serum Tricyclic Antidepressant Screen With Cyproheptadine,” <i>Clin Chem</i>, 1993, 39(6):1355-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/8504557/pubmed" id="8504557" target="_blank">8504557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34536239">
<a name="34536239"></a>Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy</i>. 2022;77(3):734-766. doi:10.1111/all.15090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/34536239/pubmed" id="34536239" target="_blank">34536239</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13194 Version 446.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
